Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Bayer    BAYN   DE000BAY0017

BAYER (BAYN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Bayer : Halts Phase 3 Study on New Xarelto Indication

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/06/2017 | 08:44am CEST
   By Sarah Sloat 
 

Bayer AG (>> Bayer) said late Thursday it halted a phase 3 study for the use of blood-thinning drug Xarelto because it didn't show improved efficacy compared with another treatment using aspirin.

The Navigate Esus study was testing Xarelto for the secondary prevention of strokes and systemic embolism in patients who recently had an embolic stroke of undetermined source.

Researchers stopped the trial early because the Xarelto and aspirin arms of the study showed comparable efficacy, and there was little chance of an overall benefit if it were completed, the German pharmaceutical and chemicals company said.

"While bleeding rates were low overall, an increase in bleeding was observed in the [Xarelto] arm compared to the low-dose aspirin arm," Bayer said.

Xarelto, also known as rivaroxaban, is a prescription anticoagulant which been approved for seven indications. The drug contributed just over 2.9 billion euros ($3.4 billion) in sales to Bayer's pharmaceutical division last year.

The drug was developed jointly by Bayer and Janssen Pharmaceuticals, a unit of Johnson & Johnson (>> Johnson & Johnson). It is marketed outside the U.S. by Bayer and within the U.S. by Janssen.

Write to Sarah Sloat at [email protected]

Stocks mentioned in the article : Bayer, Johnson & Johnson
Stocks mentioned in the article
ChangeLast1st jan.
JOHNSON & JOHNSON -1.43% 125.93 Delayed Quote.-9.87%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BAYER
07/12BAYER : Findings from Bayer in the Area of Medical Statistics Described (A Bayes..
AQ
07/12Lanxess water treatment unit attracts interest - sources
RE
07/10BAYER : U.S. judge allows lawsuits over Monsanto's Roundup to proceed to trial
RE
07/06BAYER : expands strategic alliance with Broad Institute of MIT and Harvard
AQ
07/06BAYER : Greenberg Traurig Advised Tecnoquimicas on Acquisition of MK Generics Bu..
AQ
07/05BAYER : Findings from Bayer Reveals New Findings on Personalized Medicine (Recen..
AQ
07/04Thyssenkrupp, Tata Steel may need asset sales to get EU nod for JV
RE
07/04BAYER : Animal Health and Mitsui Chemicals Agro sign global license agreement
PU
07/03Bayer sees Brazil as key growth driver for global crop division
RE
06/30BAYER : Broad and Bayer Expand Partnership, Launching New Research Effort to Dev..
AQ
More news
News from SeekingAlpha
07/123 THINGS IN BIOTECH, JULY 12 : Immunotherapy Brawl, And A Creeper In The Weeds 
07/10Judge says lawsuits alleging Roundup weedkiller causes cancer can go to trial 
07/05Bayer Animal Health in-licenses IP from Mitsui Chemicals Agro for parasiticid.. 
07/03YOUR DAILY PHARMA SCOOP : Redhill's New Patent, Nuvectra Slips, Teligent Gains 
07/03U.S. CORPORATE BOND MARKET BRACES FO : Bloomberg 
Financials (€)
Sales 2018 39 181 M
EBIT 2018 7 781 M
Net income 2018 4 973 M
Debt 2018 33 285 M
Yield 2018 2,98%
P/E ratio 2018 18,88
P/E ratio 2019 16,79
EV / Sales 2018 3,07x
EV / Sales 2019 2,55x
Capitalization 87 091 M
Chart BAYER
Duration : Period :
Bayer Technical Analysis Chart | BAYN | DE000BAY0017 | 4-Traders
Technical analysis trends BAYER
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 116 €
Spread / Average Target 24%
EPS Revisions
Managers
NameTitle
Werner Baumann Chairman-Management Board
Werner Wenning Chairman-Supervisory Board
Wolfgang U. Nickl Chief Financial Officer
Katharina Jansen Head-Science & Research
Hartmut Klusik Head-Human Resources, Technology & Sustainability
Sector and Competitors
1st jan.Capitalization (M$)
BAYER-8.75%101 760
JOHNSON & JOHNSON-9.87%337 763
PFIZER3.62%219 534
NOVARTIS-3.93%201 464
ROCHE HOLDING LTD.-5.60%200 973
MERCK AND COMPANY11.76%169 193